carbon-monoxide-therapy-neurodegeneration

Migration, Crosslink

📖

carbon-monoxide-therapy-neurodegeneration

active

wiki page Created: 2026-04-02T07:18:58 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-carbon-monoxide-therap

📖 Wiki Page

therapeutic1974 wordssynced 2026-04-02

Carbon Monoxide (CO) Releasing Compound Therapy for Neurodegeneration

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">carbon-monoxide-therapy-neurodegeneration</th>
</tr>
<tr>
<td class="label">Enzyme</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">HO-1</td>
<td>HMOX1</td>
</tr>
<tr>
<td class="label">HO-2</td>
<td>HMOX2</td>
</tr>
<tr>
<td class="label">CORM</td>
<td>Class</td>
</tr>
<tr>
<td class="label">CORM-2</td>
<td>Ruthenium carbonyl</td>
</tr>
<tr>
<td class="label">CORM-3</td>
<td>Ruthenium carbonyl</td>
</tr>
<tr>
<td class="label">CORM-401</td>
<td>Manganese carbonyl</td>
</tr>
<tr>
<td class="label">ALF-186</td>
<td>Metal carbonyl</td>
</tr>
<tr>
<td class="label">ALF-494</td>
<td>Iron carbonyl</td>
</tr>
<tr>
<td class="label">DI-1</td>
<td>Photoactivatable</td>
</tr>
<tr>
<td class="label">CORM</td>
<td>Company/Group</td>
</tr>
<tr>
<td class="label">CORM-2</td>
<td>Academic groups</td>
</tr>
<tr>
<td class="label">CORM-3</td>
<td>Academic groups</td>
</tr>
<tr>
<td class="label">CORM-401</td>
<td>Academic groups</td>
</tr>
<tr>
<td class="label">ALF-494</td>
<td>Academic groups</td>
</tr>
<tr>
<td class="label">Primary targets</td>
<td>HO-1, CO sensors</td>
</tr>
<tr>
<td class="label">BBB penetration</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">**Clinical

...

Carbon Monoxide (CO) Releasing Compound Therapy for Neurodegeneration

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">carbon-monoxide-therapy-neurodegeneration</th>
</tr>
<tr>
<td class="label">Enzyme</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">HO-1</td>
<td>HMOX1</td>
</tr>
<tr>
<td class="label">HO-2</td>
<td>HMOX2</td>
</tr>
<tr>
<td class="label">CORM</td>
<td>Class</td>
</tr>
<tr>
<td class="label">CORM-2</td>
<td>Ruthenium carbonyl</td>
</tr>
<tr>
<td class="label">CORM-3</td>
<td>Ruthenium carbonyl</td>
</tr>
<tr>
<td class="label">CORM-401</td>
<td>Manganese carbonyl</td>
</tr>
<tr>
<td class="label">ALF-186</td>
<td>Metal carbonyl</td>
</tr>
<tr>
<td class="label">ALF-494</td>
<td>Iron carbonyl</td>
</tr>
<tr>
<td class="label">DI-1</td>
<td>Photoactivatable</td>
</tr>
<tr>
<td class="label">CORM</td>
<td>Company/Group</td>
</tr>
<tr>
<td class="label">CORM-2</td>
<td>Academic groups</td>
</tr>
<tr>
<td class="label">CORM-3</td>
<td>Academic groups</td>
</tr>
<tr>
<td class="label">CORM-401</td>
<td>Academic groups</td>
</tr>
<tr>
<td class="label">ALF-494</td>
<td>Academic groups</td>
</tr>
<tr>
<td class="label">Primary targets</td>
<td>HO-1, CO sensors</td>
</tr>
<tr>
<td class="label">BBB penetration</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Clinical stage</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Dosing frequency</td>
<td>Daily</td>
</tr>
<tr>
<td class="label">Major toxicity</td>
<td>High doses: tissue hypoxia</td>
</tr>
</table>

Overview

Carbon monoxide (CO) releasing compound therapy represents an emerging neuroprotective approach for neurodegenerative diseases that exploits the endogenous gasotransmitter's anti-inflammatory, anti-apoptotic, and mitochondrial protection properties. CO is one of three primary gasotransmitters in the human body (alongside nitric oxide [NO] and hydrogen sulfide [H₂S]) and plays crucial roles in cellular signaling, mitochondrial function, and stress response[@corm_neuro_2023].

The therapeutic potential of CO-releasing molecules (CORMs) spans multiple neurodegenerative conditions including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis), and [Huntington's disease](/diseases/huntingtons-disease). Unlike exogenous CO gas administration, CORMs deliver controlled amounts of CO to achieve therapeutic effects without toxicity[@co_brain_2024].

The CO Gasotransmitter System {#co-system}

Endogenous CO Production

CO is produced endogenously through heme oxygenase (HO) enzyme-mediated degradation of heme:

Heme + O₂ + NADPH → Biliverdin + CO + Fe²⁺ + NADP⁺

Two HO isoforms exist with distinct physiological roles:

HO-1 (also known as HSP32) is highly inducible by oxidative stress, heat shock, inflammatory stimuli, and hypoxia. Its upregulation represents a conserved cellular protective response. HO-2 is constitutively expressed in neurons and maintains baseline CO production for physiological signaling[@ho1_neuro_2023].

CO as a Neuroprotective Agent

CO exerts multiple protective effects in the nervous system:

Mermaid diagram (expand to render)

CO-Releasing Molecule (CORM) Compounds {#corm-compounds}

CORMs are designed to release CO in a controlled manner, avoiding the toxicity associated with high CO concentrations. Several classes have been developed:

CORM-2

CORM-2 (dicobalt octacarbonyl) was one of the first CORMs developed:

Mechanism: Releases CO upon exposure to light or certain chemical conditions.

Advantages:

Well-characterized release kinetics
Widely used in preclinical studies
Good stability in organic solvents

Limitations:

Requires light activation for controlled release
Cobalt component may cause toxicity
Limited water solubility

CORM-2 has demonstrated neuroprotective effects in multiple models, including reduction of infarct size in stroke models and protection against β-amyloid toxicity[@corm_neuro_2023].

CORM-3

CORM-3 (tricarbonylchloro(glycinato)ruthenium(II)) is a water-soluble CORM:

Advantages:

Water-soluble, can be administered in aqueous solutions
Faster CO release than CORM-2
More physiologically relevant

Limitations:

Short half-life (~3 minutes)
Rapid CO release may cause tissue-specific effects

CORM-3 has shown particular promise in PD models, protecting dopaminergic neurons from 6-OHDA and MPTP toxicity[@corm_pd_2023].

CORM-401

CORM-401 is a mitochondria-targeted CORM:

Mechanism:

Triphenylphosphonium cation drives accumulation in mitochondria (ΔΨm-dependent)
CO released specifically within the mitochondrial matrix
Directly targets mitochondrial CO signaling pathways

Advantages:

Mitochondria-specific delivery
Potent at low concentrations
Protects against mitochondrial dysfunction

Limitations:

Requires intact mitochondrial membrane potential
More complex chemistry

CORM-401 has shown efficacy in models where mitochondrial dysfunction is central, including PD and ALS[@co_mito_2023].

ALF-494

ALF-494 is a novel iron-based CORM:

Advantages:

Iron-based (more biocompatible than ruthenium)
Moderate release kinetics
Reduced metal toxicity

Limitations:

Earlier development stage
Less characterization data

ALF-494 represents the next generation of CORMs with improved safety profiles.

Neuroprotective Mechanisms {#mechanisms}

Anti-Inflammatory Effects

CO modulates neuroinflammation through multiple pathways:

p38 MAPK Pathway: CO activates p38 MAPK signaling, which suppresses pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6) while promoting anti-inflammatory mediators (IL-10)[@corm_neuro_2023].

NF-κB Inhibition: CO inhibits NF-κB nuclear translocation, reducing expression of inflammatory genes. This effect is mediated through activation of p38 MAPK and upregulation of HO-1.

Microglial Modulation: CO shifts microglial activation from pro-inflammatory (M1) to anti-inflammatory (M2) phenotype, promoting tissue repair and reducing chronic neuroinflammation.

Anti-Apoptotic Signaling

CO protects neurons from apoptotic cell death through:

Bcl-2 Family: CO upregulates anti-apoptotic Bcl-2 and Bcl-xL while inhibiting pro-apoptotic Bax translocation to mitochondria[@corm_apoptosis_2022].

Caspase Inhibition: CO inhibits caspase-3 activation through the MAPK pathway, blocking the execution phase of apoptosis.

Akt Pathway: CO activates PI3K/Akt signaling, which promotes neuronal survival through phosphorylation of BAD and activation of downstream effectors.

Antioxidant Effects

The HO-1/CO system creates a beneficial antioxidant response:

HO-1 Induction: CO itself induces HO-1 expression, creating a positive feedback loop for antioxidant protection[@ho1_neuro_2023].

Ferritin Sequestration: While heme degradation releases iron (potentially pro-oxidant), this is rapidly sequestered by ferritin, which is also induced by CO. This coupling ensures antioxidant benefits outweigh pro-oxidant effects.

Nrf2 Activation: CO activates Nrf2 (Nuclear factor erythroid 2-related factor 2), the master regulator of antioxidant response genes, leading to upregulation of HO-1, NQO1, GCLM, and other antioxidant enzymes[@co_nrf2_2024].

Mitochondrial Protection

CO preserves mitochondrial function through:

Membrane Potential: CO preserves mitochondrial membrane potential (ΔΨm) and inhibits mitochondrial permeability transition pore (mPTP) opening[@co_mito_2023].

Complex IV: CO binds to cytochrome c oxidase (Complex IV), modulating its activity in a protective manner at low concentrations.

PGC-1α: CO promotes mitochondrial biogenesis through PGC-1α (PPARGC1A) activation, supporting generation of new healthy mitochondria.

Autophagy Induction

CO induces autophagy through:

mTOR Inhibition: CO inhibits mTORC1 signaling, relieving inhibition of autophagy initiation[@co_autophagy_2024].

LC3 Conversion: CO promotes LC3-I to LC3-II conversion, enhancing autophagosome formation.

Aggregate Clearance: CO-induced autophagy may enhance clearance of toxic protein aggregates including amyloid-β, tau, and α-synuclein.

Therapeutic Applications by Disease {#disease-applications}

Alzheimer's Disease {#alzheimers-disease}

CO deficiency has been documented in AD patients, with reduced HO-1 activity and CO levels in the brain. CORM therapy addresses multiple hallmarks of AD pathology:

Amyloid pathology: CORMs reduce amyloid-β aggregation and toxicity through:

Direct interaction with Aβ to prevent oligomerization
Enhanced microglial phagocytosis via Nrf2 activation
Reduced BACE1 expression and amyloid precursor protein processing

Tau pathology: CO modulates tau phosphorylation through:

Inhibition of GSK-3β activity
Reduced CDK5 activation
Enhanced protein phosphatase 2A activity

Synaptic dysfunction: CO enhances synaptic plasticity:

Promotion of long-term potentiation (LTP)
NMDA receptor modulation
Increased synaptophysin expression

Mitochondrial function: CO improves energy metabolism:

Preservation of complex IV activity
ATP production maintenance
Reduction of mitochondrial ROS

Mermaid diagram (expand to render)

Preclinical evidence: In 5xFAD and APP/PS1 mice, CORM-3 treatment reduced cortical amyloid plaque burden, improved performance in Morris water maze, and preserved hippocampal synaptic density["@corm_ad_2022"].

Parkinson's Disease {#parkinsons-disease}

Mitochondrial dysfunction is central to PD pathogenesis, making CORMs particularly relevant:

Dopaminergic neuron protection: CORMs protect against:

6-Hydroxydopamine (6-OHDA) toxicity
MPTP-induced parkinsonism
α-Synuclein-induced neurodegeneration

Mitochondrial quality control: CORMs enhance:

Mitophagy induction via PINK1/Parkin pathway
Mitochondrial biogenesis (PGC-1α activation)
Complex I activity preservation

Neuroinflammation: CORMs modulate:

Microglial activation state (M1 to M2 shift)
TNF-α and IL-1β reduction
NLRP3 inflammasome inhibition

α-Synuclein pathology: CORMs may reduce:

α-Synuclein aggregation
Phosphorylation at Ser129
Oligomer formation

Preclinical evidence: In MPTP-treated mice and 6-OHDA-lesioned rats, CORM-3 protected dopaminergic neurons, improved behavioral scores, and preserved striatal dopamine content[@corm_pd_2023].

Amyotrophic Lateral Sclerosis {#als}

ALS involves multiple pathological mechanisms that CORMs can address:

Motor neuron protection: CORMs have shown:

Protection against excitotoxicity
Preservation of neuromuscular junctions
Reduced oxidative stress in motor neurons

Glial modulation: CORMs affect:

Astrocyte reactivity reduction
Microglial modulation
Oligodendrocyte support

SOD1 models: In SOD1-G93A transgenic mice:

CORM-2 delayed disease progression
CORM-3 reduced motor neuron loss
Combination with riluzole showed synergy[@corm_als_2024]

Energy metabolism: CORMs support:

Mitochondrial function in skeletal muscle
Motor endplate maintenance
Metabolic adaptation

Huntington's Disease {#huntingtons-disease}

CO plays roles in HD through several mechanisms:

Mitochondrial dysfunction: CO improves:

Complex I-IV activity in striatal neurons
ATP production in affected brain regions
Mitochondrial dynamics (fusion/fission balance)

Transcriptional dysregulation: CO modulates:

Nrf2-mediated antioxidant response
HSF1 activation and heat shock protein expression
CBP activity in transcriptional regulation

Excitotoxicity: CO protects against:

NMDA-mediated excitotoxicity
Metabolic compromise
Calcium dysregulation

Autophagy: CO enhances:

Autophagic clearance of mutant huntingtin
mTOR-independent autophagy pathways
Lysosomal function

Clinical Development Status {#clinical-status}

As of 2026, CORM therapy for neurodegeneration remains in preclinical development:

Challenges to clinical translation:

Optimal dosing: CO has a narrow therapeutic window

Delivery: Achieving sustained CNS concentrations

Targeting: Directing CORMs to affected brain regions

Biomarkers: Defining pharmacodynamic endpoints

Metal toxicity: Ruthenium-based CORMs may cause metal accumulation

Clinical trials to watch:

Phase I studies of CORMs in non-CNS indications may provide safety data
Biomarker studies measuring CO levels and HO-1 expression in neurodegenerative patient cohorts

Comparison with Other Gasotransmitter Therapies {#comparison}

CORMs offer unique advantages:

HO-1 induction creates sustained antioxidant response
Direct mitochondrial targeting with CORM-401
Anti-apoptotic effects complement antioxidant actions

Disease Links

[Alzheimer's Disease](/diseases/alzheimers-disease) — primary indication
[Parkinson's Disease](/diseases/parkinsons-disease) — mitochondrial targeting
[Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis) — motor neuron protection
[Huntington's Disease](/diseases/huntingtons-disease) — transcriptional regulation

Mechanism Links

[Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction-neurodegeneration) — primary target
[Neuroinflammation](/mechanisms/neuroinflammation) — anti-inflammatory effects
[Oxidative Stress](/mechanisms/oxidative-stress-neurodegeneration) — antioxidant effects
[Protein Aggregation](/mechanisms/protein-aggregation-mechanisms) — anti-aggregation effects

Gasotransmitter Links

[Gasotransmitters in Neuroprotection](/mechanisms/gasotransmitters-neuroprotection) — comprehensive gasotransmitter overview
[H2S Donor Therapy](/therapeutics/h2s-donor-therapy-neurodegeneration) — related gasotransmitter therapy
[Nitric Oxide Signaling](/mechanisms/nitric-oxide-signaling-neurodegeneration) — third gasotransmitter

Enzyme/Protein Links

[HO-1 (Heme Oxygenase-1)](/proteins/heme-oxygenase-1) — CO-producing enzyme
[HO-2 (Heme Oxygenase-2)](/proteins/hmox2-protein) — constitutive CO production
[Nrf2](/proteins/nrf2) — antioxidant response regulator

External Links

[PubMed: CO neurodegeneration research](https://pubmed.ncbi.nlm.nih.gov/?term=carbon+monoxide+neurodegeneration)
[HO-1 Gene - NCBI](https://www.ncbi.nlm.nih.gov/gene/3165)
[CORM research papers](https://pubmed.ncbi.nlm.nih.gov/38567890/)

Future Directions {#future-directions}

The field of CORM therapy for neurodegeneration requires:

Improved CORMs: Development of CNS-targeted, sustained-release CORMs with reduced metal toxicity

Combination studies: Evaluation with standard-of-care and disease-modifying therapies

Biomarker development: Identification of CO activity biomarkers for clinical trials

Delivery optimization: Novel formulations (nanoparticles, liposomes) for CNS penetration

Patient selection: Identification of patients with HO-1 deficiency who may benefit most

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — 0.79 · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — 0.76 · Target: ABCA1/LDLR/SREBF2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — 0.75 · Target: TFRC
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7

Related Analyses:

[Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
[Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-carbon-monoxide-therapy-neurodegeneration

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-carbon-monoxide-therapy-neurodegeneration
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-0389ff4556a3
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-carbon-monoxide-therapy-neurodegeneration'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

558

Outgoing

736

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

carbon-monoxide-therapy-neurodegeneration

Carbon Monoxide (CO) Releasing Compound Therapy for Neurodegeneration

Carbon Monoxide (CO) Releasing Compound Therapy for Neurodegeneration

Overview

The CO Gasotransmitter System {#co-system}

Endogenous CO Production

CO as a Neuroprotective Agent

CO-Releasing Molecule (CORM) Compounds {#corm-compounds}

CORM-2

CORM-3

CORM-401

ALF-494

Neuroprotective Mechanisms {#mechanisms}

Anti-Inflammatory Effects

Anti-Apoptotic Signaling

Antioxidant Effects

Mitochondrial Protection

Autophagy Induction

Therapeutic Applications by Disease {#disease-applications}

Alzheimer's Disease {#alzheimers-disease}

Parkinson's Disease {#parkinsons-disease}

Amyotrophic Lateral Sclerosis {#als}

Huntington's Disease {#huntingtons-disease}

Clinical Development Status {#clinical-status}

Comparison with Other Gasotransmitter Therapies {#comparison}

Disease Links

Mechanism Links

Gasotransmitter Links

Enzyme/Protein Links

External Links

Future Directions {#future-directions}

💬 Discussion

📗 Cite This Artifact

carbon-monoxide-therapy-neurodegeneration

Carbon Monoxide (CO) Releasing Compound Therapy for Neurodegeneration

Carbon Monoxide (CO) Releasing Compound Therapy for Neurodegeneration

Overview

The CO Gasotransmitter System {#co-system}

Endogenous CO Production

CO as a Neuroprotective Agent

CO-Releasing Molecule (CORM) Compounds {#corm-compounds}

CORM-2

CORM-3

CORM-401

ALF-494

Neuroprotective Mechanisms {#mechanisms}

Anti-Inflammatory Effects

Anti-Apoptotic Signaling

Antioxidant Effects

Mitochondrial Protection

Autophagy Induction

Therapeutic Applications by Disease {#disease-applications}

Alzheimer's Disease {#alzheimers-disease}

Parkinson's Disease {#parkinsons-disease}

Amyotrophic Lateral Sclerosis {#als}

Huntington's Disease {#huntingtons-disease}

Clinical Development Status {#clinical-status}

Comparison with Other Gasotransmitter Therapies {#comparison}

Cross-Linking and Related Pages {#cross-linking}

Disease Links

Mechanism Links

Gasotransmitter Links

Enzyme/Protein Links

External Links

Future Directions {#future-directions}

Related Hypotheses

💬 Discussion